We selected six PDXs with different phenotypes and genomic features (Fig. 1c and Supplementary Fig. 1c)23, including three androgen receptor (AR)-positive adenocarcinomas and three AR-null tumors that express neuroendocrine markers, with a range of LeY expression (Supplementary Fig. 1a, b). The gene discussed is AR; the disease is adenocarcinoma.